We propose to continue our studies on brain mRNAs so as to better our understanding of patterns of brain gene expression, to identify and solve the structures of novel brain proteins with spatially restricted expression within the brain, and to gain insights into their functional nature and their contribution to the behavioral and physiological operation of the organism. We will use the newly developed and automated TOGA technology to identify cDNA clones of mRNAs highly enriched in their expression in the hypothalamus, so as to identify those whose expression is restricted to discrete hypothalamic nuclei, or the striatum, so as to compile a complete dossier on the molecular nature of medium spiny neurons. Full-length clones of novel ensemble members will be isolated and their sequences determined so as to team the identity of their encoded proteins. The sites of expression will be determined by in situ hybridization and unmunohistochemical methods using antisera to synthetic peptides corresponding to domains of the deduced protein sequences. We will use the acquired information to form hypotheses about function and test these by biochemical measurements on the recombinant protein expressed by bacteria or transfected manimalian cells and by gene inactivation studies. For hypocretin, an excitatory neoromodulatory peptide that is produced by a few thousand hypothalamic neurons, that has been implicated in multiple homeostatic systems, including sleep and feeding, and that is implicated in all human narcolepsies, and for cortistatin, a somatostatin-like sleep-promoting peptide of cortical inhibitory intemeurons, we will generate lines of transgenic mice that express the intracellular portions of either diphtheria toxin or cholera toxin and thus either ablate or hyperactivate the neurons that normally produce these peptides. The hypocretin-DT mice will serve as a model for HLA-linked narcolepsy, which is thought to be caused by autoimmune destruction of hypocretin neurons. We will isolate RNA from these several transgenic mouse lines and use TOGA to identify the entire ensemble of mRNAs that are selectively expressed in hypocretin and cortistatin neurons. We will characterize knockout mice with null alleles in the genes encoding: a) 5-HT7, a serotonin receptor expressed prominently in ventral hypothalamus, which is coupled to stimulation of adenylyl cyclase, and whose pharmacology we have shown to be uniquely consistent with that of the 5-HT receptor that mediates circadian phase shifts in hypothalamic slice preparations, and which is a target for the sleep-promoting effects of oleamide, b) RC3/neurogranin, a forebrain-specific calmodulin-binding phosphoprotein which has been implicated in determining the availability of calinodulin and the calcium set point in dendritic spines and possibly in the development of dendritic spines, and c) cortistatin, a neuropeptide of cortical intemeurons that antagonizes the desynchronizing effects of acetylcholine on paired pulse and EEG measurements and enhances slow wave sleep.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM032355-20
Application #
6821362
Study Section
Special Emphasis Panel (ZRG1-MDCN-5 (01))
Program Officer
Anderson, Richard A
Project Start
1983-07-01
Project End
2006-11-30
Budget Start
2004-12-01
Budget End
2006-11-30
Support Year
20
Fiscal Year
2005
Total Cost
$444,480
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Sarkisyan, Gor; Roberts, Amanda J; Hedlund, Peter B (2010) The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior. Behav Brain Res 209:99-108
Tang, Bin; Chang, Wei-li; Lanigan, Caroline M et al. (2009) Normal human aging and early-stage schizophrenia share common molecular profiles. Aging Cell 8:339-42
Semenova, Svetlana; Geyer, Mark A; Sutcliffe, J Gregor et al. (2008) Inactivation of the 5-HT(7) receptor partially blocks phencyclidine-induced disruption of prepulse inhibition. Biol Psychiatry 63:98-105
Desplats, Paula A; Kass, Kristi E; Gilmartin, Tim et al. (2006) Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J Neurochem 96:743-57
de Lecea, Luis; Sutcliffe, J Gregor (2005) The hypocretins and sleep. FEBS J 272:5675-88
Hedlund, Peter B; Huitron-Resendiz, Salvador; Henriksen, Steven J et al. (2005) 5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern. Biol Psychiatry 58:831-7
Ziolkowska, Barbara; Gieryk, Agnieszka; Bilecki, Wiktor et al. (2005) Regulation of alpha-synuclein expression in limbic and motor brain regions of morphine-treated mice. J Neurosci 25:4996-5003
Roberts, Amanda J; Krucker, Thomas; Levy, Coree L et al. (2004) Mice lacking 5-HT receptors show specific impairments in contextual learning. Eur J Neurosci 19:1913-22
Bonaventure, P; Nepomuceno, D; Hein, L et al. (2004) Radioligand binding analysis of knockout mice reveals 5-hydroxytryptamine(7) receptor distribution and uncovers 8-hydroxy-2-(di-n-propylamino)tetralin interaction with alpha(2) adrenergic receptors. Neuroscience 124:901-11
Hedlund, Peter B; Kelly, Lisa; Mazur, Curt et al. (2004) 8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors to induce hypothermia in rodents. Eur J Pharmacol 487:125-32

Showing the most recent 10 out of 82 publications